federal
trade
commission
actavis
et
argued
march
decided
june
drug
price
competition
patent
term
restoration
act
act
act
creates
special
procedures
identifying
resolving
patent
disputes
generic
drug
manufacturers
one
requires
prospective
generic
manufacturer
assure
food
drug
administration
fda
infringe
patents
one
way
provide
assurance
paragraph
iv
route
certifying
listed
relevant
patent
invalid
infringed
manufacture
use
sale
generic
drug
vii
iv
respondent
solvay
pharmaceuticals
obtained
patent
approved
drug
androgel
subsequently
respondents
actavis
paddock
filed
applications
generic
drugs
modeled
androgel
certified
paragraph
iv
solvay
patent
invalid
drugs
infringe
solvay
sued
actavis
paddock
claiming
patent
infringement
see
fda
eventually
approved
actavis
generic
product
instead
bringing
drug
market
actavis
entered
reverse
payment
settlement
agreement
solvay
agreeing
bring
generic
market
specified
number
years
agreeing
promote
androgel
doctors
exchange
millions
dollars
paddock
made
similar
agreement
solvay
respondent
par
another
manufacturer
aligned
patent
litigation
paddock
federal
trade
commission
ftc
filed
suit
alleging
respondents
violated
federal
trade
commission
act
unlawfully
agreeing
abandon
patent
challenges
refrain
launching
generic
drugs
share
solvay
monopoly
profits
district
dismissed
complaint
eleventh
circuit
concluded
long
anticompetitive
effects
settlement
fall
within
scope
patent
exclusionary
potential
settlement
immune
antitrust
attack
noting
ftc
alleged
challenged
agreements
excluded
competition
greater
extent
patent
valid
affirmed
complaint
dismissal
recognized
parties
sort
case
settle
might
declare
patent
invalid
since
public
policy
favors
settlement
disputes
held
courts
require
parties
continue
litigate
order
avoid
antitrust
liability
held
eleventh
circuit
erred
affirming
dismissal
ftc
complaint
pp
although
anticompetitive
effects
reverse
settlement
agreement
might
fall
within
scope
exclusionary
potential
solvay
patent
immunize
agreement
antitrust
attack
one
thing
refer
simply
holder
valid
patent
answer
antitrust
question
paragraph
iv
litigation
put
patent
validity
preclusive
scope
issue
parties
settlement
ftc
alleges
plaintiff
agreed
pay
defendants
millions
stay
market
even
though
defendants
monetary
claim
plaintiff
ended
litigation
form
settlement
unusual
reason
concern
settlements
tend
significant
adverse
effects
competition
incongruous
determine
antitrust
legality
measuring
settlement
anticompetitive
effects
solely
patent
law
policy
procompetitive
antitrust
policies
well
relevant
determining
scope
monopoly
antitrust
immunity
conferred
patent
see
line
material
antitrust
question
answered
considering
traditional
antitrust
factors
another
thing
precedents
make
clear
settlement
agreements
sometimes
violate
antitrust
laws
see
singer
mfg
new
wrinkle
standard
oil
indiana
finally
act
general
procompetitive
thrust
facilitating
challenges
patent
validity
requiring
parties
paragraph
iv
dispute
report
settlement
terms
federal
antitrust
regulators
suggests
view
contrary
eleventh
circuit
pp
eleventh
circuit
conclusion
finds
support
general
legal
policy
favoring
settlement
disputes
related
underlying
practical
concern
consists
fear
antitrust
scrutiny
reverse
payment
agreement
require
parties
engage
complex
expensive
litigation
demonstrate
happened
competition
absent
settlement
however
five
sets
considerations
lead
conclusion
concern
determine
result
ftc
given
opportunity
prove
antitrust
claim
first
specific
restraint
issue
potential
genuine
adverse
effects
competition
ftc
indiana
federation
dentists
payment
staying
market
keeps
prices
levels
divides
benefit
patentee
challenger
consumer
loses
two
act
features
advantage
given
first
paragraph
iv
challenger
win
fda
approval
iv
roughly
period
subsequent
manufacturers
required
wait
winning
fda
approval
iii
mean
reverse
settlement
agreement
first
filer
removes
consideration
manufacturer
likely
introduce
competition
quickly
second
anticompetitive
consequences
least
sometimes
prove
unjustified
may
justifications
reverse
payment
result
sought
brought
anticompetitive
consequences
justify
dismissing
ftc
complaint
without
examining
potential
justifications
third
reverse
payment
threatens
work
unjustified
anticompetitive
harm
patentee
likely
power
bring
harm
practice
size
payment
branded
drug
manufacturer
generic
challenger
strong
indicator
power
fourth
antitrust
action
likely
prove
feasible
administratively
eleventh
circuit
believed
normally
necessary
litigate
patent
validity
answer
antitrust
question
large
unexplained
reverse
payment
provide
workable
surrogate
patent
weakness
without
forcing
conduct
detailed
exploration
patent
validity
fifth
fact
large
unjustified
reverse
payment
risks
antitrust
liability
prevent
litigating
parties
settling
lawsuits
industries
may
settle
ways
allowing
generic
manufacturer
enter
patentee
market
patent
expires
without
patentee
paying
challenger
stay
prior
point
pp
declines
hold
reverse
payment
settlement
agreements
presumptively
unlawful
courts
reviewing
agreements
proceed
applying
rule
reason
rather
quick
look
approach
see
california
dental
assn
ftc
pp
reversed
remanded
breyer
delivered
opinion
kennedy
ginsburg
sotomayor
kagan
joined
roberts
filed
dissenting
opinion
scalia
thomas
joined
alito
took
part
consideration
decision
case
opinion
notice
opinion
subject
formal
revision
publication
preliminary
print
reports
readers
requested
notify
reporter
decisions
washington
typographical
formal
errors
order
corrections
may
made
preliminary
print
goes
press
federal
trade
commission
petitioner
actavis
et
al
writ
certiorari
appeals
eleventh
circuit
june
justice
breyer
delivered
opinion
company
sues
company
patent
infringement
two
companies
settle
terms
require
company
claimed
infringer
produce
product
patent
term
expires
company
patentee
pay
many
millions
dollars
settlement
requires
patentee
pay
alleged
infringer
rather
way
around
kind
settlement
agreement
often
called
reverse
payment
settlement
agreement
basic
question
whether
agreement
sometimes
unreasonably
diminish
competition
violation
antitrust
laws
see
sherman
act
prohibition
restraint
trade
commerce
cf
palmer
brg
per
curiam
invalidating
agreement
compete
case
eleventh
circuit
dismissed
federal
trade
commission
ftc
complaint
claiming
particular
reverse
payment
settlement
agreement
violated
antitrust
laws
circuit
stated
reverse
payment
settlement
agreement
generally
immune
antitrust
attack
long
anticompetitive
effects
fall
within
scope
exclusionary
potential
patent
ftc
watson
pharmaceuticals
since
alleged
infringer
promise
enter
patentee
market
expired
patent
term
ended
circuit
found
agreement
legal
dismissed
ftc
complaint
view
however
reverse
payment
settlements
agreement
alleged
complaint
us
violate
antitrust
laws
consequently
hold
eleventh
circuit
allowed
ftc
lawsuit
proceed
apparently
reverse
payment
settlement
agreements
arise
context
pharmaceutical
drug
regulation
specifically
context
suits
brought
statutory
provisions
allowing
generic
drug
manufacturer
seeking
speedy
marketing
approval
challenge
validity
patent
owned
drug
owner
see
brief
petitioner
areeda
hovenkamp
antitrust
law
ed
hereinafter
areeda
hovenkamp
sensible
antitrust
rules
pharmaceutical
competition
rev
consequently
describe
four
key
features
relevant
framework
established
drug
price
competition
patent
term
restoration
act
stat
amended
act
commonly
known
act
first
drug
manufacturer
wishing
market
new
prescription
drug
must
submit
new
drug
application
federal
food
drug
administration
fda
undergo
long
comprehensive
costly
testing
process
successful
manufacturer
receive
marketing
approval
fda
see
requiring
among
things
full
reports
investigations
safety
effectiveness
full
list
articles
used
components
full
description
drug
manufactured
processed
packed
second
fda
approved
drug
marketing
manufacturer
generic
drug
obtain
similar
marketing
approval
use
procedures
act
permits
generic
manufacturer
file
abbreviated
new
drug
specifying
generic
active
ingredients
biologically
equivalent
drug
caraco
pharmaceutical
laboratories
novo
nordisk
slip
citing
ii
iv
way
generic
manufacturer
obtain
approval
avoiding
costly
studies
needed
obtain
approval
pioneer
drug
see
eli
lilly
medtronic
process
allowing
generic
pioneer
approval
efforts
speed
introduction
generic
drugs
market
caraco
supra
slip
thereby
furthering
drug
competition
third
act
sets
forth
special
identifying
resolving
related
patent
requires
pioneer
manufacturer
list
new
drug
application
number
expiration
date
relevant
patent
see
requires
generic
manufacturer
abbreviated
new
drug
application
assure
fda
generic
infringe
patents
see
caraco
supra
slip
generic
provide
assurance
one
several
ways
see
vii
certify
manufacturer
listed
relevant
patents
certify
relevant
patents
expired
request
approval
market
beginning
patents
expire
certify
listed
relevant
patent
invalid
infringed
manufacture
use
sale
drug
described
abbreviated
new
drug
application
see
vii
iv
taking
route
called
paragraph
iv
route
automatically
counts
patent
infringement
see
supp
often
means
provoking
litigation
caraco
supra
slip
patentee
brings
infringement
suit
within
days
fda
must
withhold
approving
generic
usually
period
parties
litigate
patent
validity
infringement
courts
decide
matter
within
period
fda
follows
determination
fda
may
go
forward
give
approval
market
generic
product
see
iii
fourth
provides
special
incentive
generic
first
file
abbreviated
new
drug
application
taking
paragraph
iv
route
applicant
enjoy
period
days
exclusivity
first
commercial
marketing
drug
see
iv
establishing
exclusivity
period
period
exclusivity
generic
compete
drug
generic
manufacturer
overcome
patent
obstacle
bring
generic
market
period
exclusivity
prove
valuable
possibly
worth
several
hundred
million
dollars
hemphill
paying
delay
pharmaceutical
patent
settlement
regulatory
design
problem
rev
indeed
generic
pharmaceutical
association
said
majority
potential
profits
generic
drug
manufacturer
materialize
exclusivity
period
brief
petitioner
quoting
statement
exclusivity
period
however
belong
first
generic
file
generic
forfeit
exclusivity
right
one
ways
specified
statute
generic
obtain
see
solvay
pharmaceuticals
respondent
filed
new
drug
application
drug
called
androgel
fda
approved
application
solvay
obtained
relevant
patent
disclosed
fact
fda
requires
see
requiring
addition
fda
must
publish
new
patent
information
upon
submission
later
year
another
respondent
actavis
known
watson
pharmaceuticals
filed
abbreviated
new
drug
application
generic
drug
modeled
androgel
subsequently
paddock
laboratories
also
respondent
separately
filed
abbreviated
new
drug
application
generic
product
actavis
paddock
certified
paragraph
iv
solvay
listed
patent
invalid
drugs
infringe
fourth
manufacturer
par
pharmaceutical
likewise
respondent
file
application
joined
forces
paddock
agreeing
share
patent
litigation
costs
return
share
profits
paddock
obtained
approval
generic
drug
solvay
initiated
paragraph
iv
patent
litigation
actavis
paddock
thirty
months
later
fda
approved
actavis
generic
product
parties
settled
terms
settlement
actavis
agreed
bring
generic
market
august
months
solvay
patent
expired
unless
someone
else
marketed
generic
sooner
actavis
also
agreed
promote
androgel
urologists
generic
manufacturers
made
roughly
similar
promises
solvay
agreed
pay
millions
dollars
generic
million
total
paddock
million
total
par
estimated
million
annually
nine
years
actavis
see
app
complaint
companies
described
payments
compensation
services
generics
promised
perform
ftc
contends
services
little
value
according
ftc
true
point
payments
compensate
generics
agreeing
compete
androgel
see
complaint
january
ftc
filed
lawsuit
settling
parties
namely
solvay
actavis
paddock
par
ftc
complaint
since
amended
alleged
respondents
violated
federal
trade
commission
act
unlawfully
agreeing
share
solvay
monopoly
profits
abandon
patent
challenges
refrain
launching
generic
products
compete
androgel
nine
years
app
complaint
see
generally
ftc
indiana
federation
dentists
section
encompass
es
practices
violate
sherman
act
antitrust
laws
district
held
allegations
set
forth
antitrust
law
violation
androgel
antitrust
litigation
ii
supp
nd
accordingly
dismissed
ftc
complaint
ftc
appealed
appeals
eleventh
circuit
affirmed
district
wrote
absent
sham
litigation
fraud
obtaining
patent
reverse
payment
settlement
immune
antitrust
attack
long
anticompetitive
effects
fall
within
scope
exclusionary
potential
patent
recognized
antitrust
laws
typically
prohibit
agreements
one
company
pays
potential
competitor
enter
market
citing
valley
drug
geneva
pharmaceuticals
see
also
palmer
agreement
divide
territorial
markets
held
unlawful
face
found
reverse
payment
settlements
patent
litigation
presen
atypical
cases
one
parties
owns
patent
internal
quotation
marks
second
alteration
omitted
patent
holders
lawful
right
exclude
others
market
ibid
internal
quotation
marks
omitted
thus
patent
conveys
right
cripple
competition
internal
quotation
marks
omitted
recognized
parties
sort
case
settle
might
declare
patent
invalid
light
public
policy
favoring
settlement
disputes
among
considerations
held
courts
require
parties
continue
litigate
order
avoid
antitrust
liability
ftc
sought
certiorari
different
courts
reached
different
conclusions
application
antitrust
laws
patent
settlements
granted
ftc
petition
compare
case
settlements
generally
immune
antitrust
attack
ciprofloxacin
hydrochloride
antitrust
litigation
ca
fed
similar
tamoxifen
citrate
antitrust
litigation
similar
antitrust
litigation
settlements
presumptively
unlawful
ii
solvay
patent
valid
infringed
might
permitted
charge
drug
prices
sufficient
recoup
reverse
settlement
payments
agreed
make
potential
generic
competitors
willing
take
fact
evidence
agreement
anticompetitive
effects
fall
within
scope
exclusionary
potential
patent
agree
fact
characterization
immunize
agreement
antitrust
attack
one
thing
refer
circuit
referred
simply
holder
valid
patent
answer
antitrust
question
patent
may
may
valid
may
may
infringed
valid
patent
excludes
except
owner
use
protected
process
product
line
material
emphasis
added
exclusion
may
permit
patent
owner
charge
price
patented
product
invalidated
patent
carries
right
even
valid
patent
confers
right
exclude
products
processes
actually
infringe
paragraph
iv
litigation
case
put
patent
validity
issue
well
actual
preclusive
scope
parties
settlement
ended
litigation
ftc
alleges
substance
plaintiff
agreed
pay
defendants
many
millions
dollars
stay
market
even
though
defendants
claim
plaintiff
liable
damages
form
settlement
unusual
reasons
discussed
part
infra
reason
concern
settlements
taking
form
tend
significant
adverse
effects
competition
given
factors
incongruous
determine
antitrust
legality
measuring
settlement
anticompetitive
effects
solely
patent
law
policy
rather
measuring
procompetitive
antitrust
policies
well
indeed
contrary
circuit
view
pertinent
question
whether
settlement
agreement
fall
within
legitimate
scope
patent
exclusionary
potential
indicated
patent
antitrust
policies
relevant
determining
scope
patent
monopoly
consequently
antitrust
law
immunity
conferred
patent
thus
line
material
explained
improper
use
patent
monopoly
invalid
antitrust
laws
resolved
antitrust
question
case
seeking
accommodation
lawful
restraint
trade
patent
monopoly
illegal
restraint
prohibited
broadly
sherman
act
strike
balance
asked
questions
whether
patent
statute
specifically
gives
right
restrain
competition
manner
challenged
whether
competition
impeded
greater
degree
restraint
issue
restraints
previously
approved
reasonable
see
also
gypsum
courts
must
balance
privileges
patent
holder
licensees
patent
grants
prohibitions
sherman
act
combinations
attempts
monopolize
walker
process
equipment
food
machinery
chemical
nforcement
patent
procured
fraud
may
violate
sherman
act
short
rather
measure
length
amount
restriction
solely
length
patent
term
earning
potential
appeals
apparently
answered
antitrust
question
considering
traditional
antitrust
factors
likely
anticompetitive
effects
redeeming
virtues
market
power
potentially
offsetting
legal
considerations
present
circumstances
related
patents
see
part
infra
whether
particular
restraint
lies
beyond
limits
patent
monopoly
conclusion
flows
analysis
chief
justice
suggests
starting
point
post
dissenting
opinion
another
thing
precedents
make
clear
settlement
agreements
sometimes
violate
antitrust
laws
singer
mfg
example
two
sewing
machine
companies
possessed
competing
patent
claims
third
company
sought
patent
circumstances
might
lead
disclosure
information
invalidate
two
firms
patents
three
firms
settled
disagreements
assigning
broadest
claims
firm
best
able
enforce
patent
yet
potential
competitors
examine
whether
assumption
three
patents
valid
patent
law
allowed
patents
holders
rather
emphasizing
sherman
act
imposes
strict
limitations
concerted
activities
patent
owners
may
lawfully
engage
held
agreements
although
settling
patent
disputes
violated
antitrust
laws
important
part
public
interest
granting
patent
monopolies
exists
extent
public
given
novel
useful
invention
consideration
grant
white
concurring
see
also
new
wrinkle
applying
antitrust
scrutiny
patent
settlement
standard
oil
indiana
similarly
within
settlement
context
without
struck
overly
restrictive
patent
licensing
agreements
irrespective
whether
agreements
produced
revenues
concede
general
elec
permitted
single
patentee
grant
single
licensee
license
containing
minimum
resale
price
requirement
line
material
supra
held
antitrust
laws
forbid
group
patentees
owning
one
patents
insist
licensee
maintain
retail
prices
set
collectively
patent
holders
willing
presume
practice
approved
general
electric
reasonable
restraint
accords
patent
monopoly
granted
patent
law
declined
extend
conclusion
agreements
sherman
act
prohibits
agreements
fix
prices
arrangement
patentees
runs
afoul
prohibition
outside
patent
monopoly
ibid
new
wrinkle
held
roughly
time
respect
similar
arrangement
settlement
litigation
two
patentees
contended
patent
gave
exclusive
right
control
production
one
company
may
presume
right
patent
lead
confer
antitrust
immunity
far
agreement
found
violate
sherman
act
finally
standard
oil
indiana
upheld
agreements
among
patentees
settled
actual
impending
patent
litigation
agreements
set
royalty
rates
charged
third
parties
license
practice
patents
issue
divided
resulting
revenues
justice
brandeis
writing
warned
arrangement
violated
sherman
act
patent
holders
thereby
dominate
industry
curtail
ed
manufacture
supply
unpatented
product
cases
simply
ask
whether
hypothetically
valid
patent
holder
able
charge
high
prices
challenged
term
allowed
rather
seek
patent
antitrust
policies
finding
challenged
terms
conditions
unlawful
unless
patent
law
policy
offsets
antitrust
law
policy
strongly
favoring
competition
thus
contrary
dissent
suggestion
post
nothing
novel
approach
appear
novel
dissent
suggestions
patent
holder
may
simply
pa
competitor
respect
patent
quit
patent
invalidity
noninfringement
claim
without
antitrust
scrutiny
whatever
post
settlements
feature
intellectual
property
litigation
post
closer
examination
casts
doubt
claims
dissent
identify
patent
statute
understands
grant
right
patentee
whether
expressly
fair
implication
difficult
reconcile
proposed
right
policy
eliminating
unwarranted
patent
grants
public
continually
required
pay
tribute
monopolists
without
need
justification
lear
adkins
authorities
cited
proposition
none
none
antitrust
case
point
say
company
sues
company
patent
infringement
demands
say
million
damages
uncommon
defendant
pay
plaintiff
amount
less
full
demand
part
settlement
million
example
see
schildkraut
settlements
reverse
payment
fallacy
antitrust
suggesting
hypothetical
settlement
includes
implicit
net
payment
million
amount
settlement
discount
cited
authorities
also
indicate
counterclaim
damages
original
infringement
plaintiff
might
end
paying
settle
counterclaim
cf
mayer
safety
describing
trademark
dispute
settlement
insofar
dissent
urges
settlements
taking
commonplace
forms
thought
reason
alone
subject
antitrust
liability
agree
intend
alter
understanding
dissent
appears
also
suggest
reverse
payment
settlements
plaintiff
pays
money
defendant
purely
give
patent
fight
viewed
antitrust
purposes
light
familiar
settlement
forms
see
post
agree
traditional
examples
cited
party
claim
counterclaim
damages
receives
sum
equal
less
value
claim
reverse
payment
settlements
contrast
party
claim
damages
something
usually
true
paragraph
iv
litigation
defendant
walks
away
money
simply
stay
away
patentee
market
think
something
quite
different
cf
verizon
communications
law
offices
curtis
trinko
llp
ollusion
evil
antitrust
finally
act
embody
statutory
policy
supports
eleventh
circuit
view
rather
general
procompetitive
thrust
statute
specific
provisions
facilitating
challenges
patent
validity
see
part
supra
provisions
requiring
parties
patent
dispute
triggered
paragraph
iv
filing
report
settlement
terms
ftc
antitrust
division
department
justice
suggest
contrary
see
stat
interested
legislative
history
may
also
wish
examine
statements
individual
members
congress
condemning
reverse
payment
settlements
advance
amendments
see
cong
rec
remarks
hatch
clear
act
designed
allow
deals
brand
generic
companies
delay
competition
cong
rec
remarks
waxman
introducing
bill
deter
companies
strik
ing
collusive
agreements
trade
multimillion
dollar
payoffs
brand
company
delays
introduction
lower
cost
generic
alternatives
eleventh
circuit
conclusion
finds
degree
support
general
legal
policy
favoring
settlement
disputes
see
also
ftc
tamoxifen
citrate
noting
public
interest
complex
expensive
cases
circuit
related
underlying
practical
concern
consists
fear
antitrust
scrutiny
reverse
payment
agreement
require
parties
litigate
validity
patent
order
demonstrate
happened
competition
absence
settlement
litigation
prove
time
consuming
complex
expensive
antitrust
game
circuit
may
believe
worth
litigation
candle
recognize
value
settlements
patent
litigation
problem
nonetheless
conclude
factor
determine
result
rather
five
sets
considerations
lead
us
conclude
ftc
given
opportunity
prove
antitrust
claim
first
specific
restraint
issue
potential
genuine
adverse
effects
competition
indiana
federation
dentists
citing
areeda
payment
effect
amounts
purchase
patentee
exclusive
right
sell
product
right
already
claims
lose
patent
litigation
continue
patent
held
invalid
infringed
generic
product
suppose
example
exclusive
right
sell
produces
million
supracompetitive
profits
per
year
patentee
suppose
patent
years
run
continued
litigation
results
patent
invalidation
finding
noninfringement
cost
patentee
million
lost
revenues
sum
flow
large
part
consumers
form
lower
prices
concede
settlement
terms
permitting
patent
challenger
enter
market
patent
expires
also
bring
competition
consumer
benefit
settlement
terms
said
ftc
issue
payment
return
staying
market
simply
keeps
prices
levels
potentially
producing
full
million
monopoly
return
dividing
return
challenged
patentee
patent
challenger
patentee
challenger
gain
consumer
loses
indeed
indications
patentees
sometimes
pay
generic
challenger
sum
even
larger
generic
gain
profits
paragraph
iv
litigation
entered
market
see
hemphill
see
also
brief
law
economics
business
professors
et
al
amici
curiae
estimating
true
settlement
challenged
rationale
behind
payment
size
every
case
supported
traditional
settlement
considerations
payment
may
instead
provide
strong
evidence
patentee
seeks
induce
generic
challenger
abandon
claim
share
monopoly
profits
otherwise
lost
competitive
market
one
might
ask
practical
matter
parties
able
enter
anticompetitive
agreement
high
reverse
payment
signal
potential
challengers
patentee
lacks
confidence
patent
thereby
provoking
additional
challenges
perhaps
many
patentee
buy
two
special
features
mean
answer
question
necessarily
first
first
challenger
gains
special
advantage
days
exclusive
right
sell
generic
version
product
see
part
supra
noted
right
proved
valuable
indeed
worth
several
hundred
million
dollars
see
hemphill
supra
brief
petitioner
subsequent
challengers
secure
exclusivity
period
thus
stand
win
significantly
less
first
bring
successful
paragraph
iv
challenge
subsequent
litigation
results
invalidation
patent
ruling
patent
infringed
litigation
victory
free
challenger
compete
potential
competitors
obtain
fda
approval
potential
reward
available
subsequent
challenger
significantly
less
patentee
payment
initial
challenger
return
pressing
patent
challenge
necessarily
provoke
subsequent
challenges
second
generic
files
paragraph
iv
learning
first
filer
settled
sued
wait
stay
period
roughly
months
fda
may
approve
application
first
filer
see
iii
features
together
mean
reverse
payment
settlement
first
filer
case
initial
filers
removes
consideration
motivated
challenger
one
closest
introducing
competition
hemphill
supra
dissent
may
doubt
provisions
matter
post
scholars
field
tell
us
one
party
owns
patent
virtually
unheard
outside
pharmaceuticals
party
pay
accused
infringer
settle
lawsuit
hovenkamp
janis
lemley
leslie
ip
antitrust
ed
supp
may
well
unique
regulatory
framework
including
special
advantage
exclusivity
period
gives
first
filers
much
explain
context
others
patentee
ordinary
incentives
resist
paying
challengers
fear
provoking
myriad
challengers
appear
frequently
overcome
see
areeda
ed
noting
provisions
doubt
unintentionally
created
special
incentives
collusion
second
anticompetitive
consequences
least
sometimes
prove
unjustified
see
ed
california
dental
assn
ftc
breyer
concurring
part
dissenting
part
ftc
admits
offsetting
redeeming
virtues
sometimes
present
brief
petitioner
reverse
payment
example
may
amount
rough
approximation
litigation
expenses
saved
settlement
payment
may
reflect
compensation
services
generic
promised
perform
distributing
patented
item
helping
develop
market
item
may
justifications
reverse
payment
reflects
traditional
settlement
considerations
avoided
litigation
costs
fair
value
services
concern
patentee
using
monopoly
profits
avoid
risk
patent
invalidation
finding
noninfringement
cases
parties
may
provided
reverse
payment
without
sought
brought
anticompetitive
consequences
mentioned
possibility
justify
dismissing
ftc
complaint
antitrust
defendant
may
show
antitrust
proceeding
legitimate
justifications
present
thereby
explaining
presence
challenged
term
showing
lawfulness
term
rule
reason
see
indiana
federation
dentists
supra
areeda
ed
third
reverse
payment
threatens
work
unjustified
anticompetitive
harm
patentee
likely
possesses
power
bring
harm
practice
see
least
size
payment
branded
drug
manufacturer
prospective
generic
strong
indicator
power
namely
power
charge
prices
higher
competitive
level
important
patent
helps
assure
power
neither
firm
without
power
likely
pay
large
sums
induce
others
stay
market
ibid
event
commission
referred
studies
showing
reverse
payment
agreements
associated
presence
profits
strong
indication
market
power
see
brief
petitioner
fourth
antitrust
action
likely
prove
feasible
administratively
eleventh
circuit
believed
circuit
holding
avoid
need
litigate
patent
validity
also
question
infringement
throws
baby
bath
water
need
take
drastic
step
normally
necessary
litigate
patent
validity
answer
antitrust
question
unless
perhaps
determine
whether
patent
litigation
sham
see
unexplained
large
reverse
payment
normally
suggest
patentee
serious
doubts
patent
survival
fact
turn
suggests
payment
objective
maintain
supracompetitive
prices
shared
among
patentee
challenger
rather
face
might
competitive
market
anticompetitive
consequence
underlies
claim
antitrust
unlawfulness
owner
particularly
valuable
patent
might
contend
course
even
small
risk
invalidity
justifies
large
payment
may
payment
otherwise
unexplained
likely
seeks
prevent
risk
competition
said
consequence
constitutes
relevant
anticompetitive
harm
word
size
unexplained
reverse
payment
provide
workable
surrogate
patent
weakness
without
forcing
conduct
detailed
exploration
validity
patent
areeda
fifth
fact
large
unjustified
reverse
payment
risks
antitrust
liability
prevent
litigating
parties
settling
lawsuit
may
industries
settle
ways
example
allowing
generic
manufacturer
enter
patentee
market
prior
patent
expiration
without
patentee
paying
challenger
stay
prior
point
although
parties
may
reasons
prefer
settlements
include
reverse
payments
relevant
antitrust
question
reasons
basic
reason
desire
maintain
share
monopoly
profits
absence
justification
antitrust
laws
likely
forbid
arrangement
sum
reverse
payment
large
unjustified
bring
risk
significant
anticompetitive
effects
one
makes
payment
may
unable
explain
justify
firm
individual
may
well
possess
market
power
derived
patent
examining
size
payment
may
well
able
assess
likely
anticompetitive
effects
along
potential
justifications
without
litigating
validity
patent
parties
may
well
find
ways
settle
patent
disputes
without
use
reverse
payments
view
considerations
taken
together
outweigh
single
strong
consideration
desirability
settlements
led
eleventh
circuit
provide
antitrust
immunity
reverse
payment
settlements
iii
ftc
urges
us
hold
reverse
payment
settlement
agreements
presumptively
unlawful
courts
reviewing
agreements
proceed
via
quick
look
approach
rather
applying
rule
reason
see
california
dental
analysis
effect
shifts
defendant
burden
show
empirical
evidence
procompetitive
effects
areeda
ed
decline
california
dental
held
unanimously
abandonment
rule
reason
favor
presumptive
rules
approach
appropriate
observer
even
rudimentary
understanding
economics
conclude
arrangements
question
anticompetitive
effect
customers
markets
breyer
concurring
part
dissenting
part
believe
reverse
payment
settlements
context
discuss
meet
criterion
likelihood
reverse
payment
bringing
anticompetitive
effects
depends
upon
size
scale
relation
payor
anticipated
future
litigation
costs
independence
services
might
represent
payment
lack
convincing
justification
existence
degree
anticompetitive
consequence
may
also
vary
among
industries
complexities
lead
us
conclude
ftc
must
prove
case
cases
say
require
courts
insist
contrary
said
commission
need
litigate
patent
validity
empirically
demonstrate
virtues
vices
patent
system
present
every
possible
supporting
fact
refute
every
possible
theory
leading
antitrust
scholar
pointed
always
something
sliding
scale
appraising
quality
proof
required
vary
circumstances
california
dental
supra
quoting
approval
areeda
areas
law
trial
courts
structure
antitrust
litigation
avoid
one
hand
use
antitrust
theories
abbreviated
permit
proper
analysis
consideration
every
possible
fact
theory
irrespective
minimal
light
may
shed
basic
question
presence
unjustified
anticompetitive
consequences
see
therefore
leave
lower
courts
structuring
present
antitrust
litigation
reverse
judgment
eleventh
circuit
remand
case
proceedings
consistent
opinion
ordered
justice
alito
took
part
consideration
decision
case
roberts
dissenting
federal
trade
commission
petitioner
actavis
et
al
writ
certiorari
appeals
eleventh
circuit
june
chief
justice
roberts
justice
scalia
justice
thomas
join
dissenting
solvay
pharmaceuticals
holds
patent
sued
two
generic
drug
manufacturers
alleged
infringing
patent
companies
counterclaimed
contending
patent
invalid
event
products
infringe
parties
litigated
three
years
settling
terms
solvay
agreed
pay
generics
millions
dollars
allow
market
five
years
patent
set
expire
exchange
generics
agreed
provide
certain
services
help
marketing
manufacturing
honor
solvay
patent
federal
trade
commission
alleges
settlement
violates
antitrust
laws
question
assess
claim
patent
carves
exception
applicability
antitrust
laws
correct
approach
therefore
ask
whether
settlement
gives
solvay
monopoly
power
beyond
patent
already
gave
however
departs
approach
instead
use
antitrust
law
amorphous
rule
reason
inquire
anticompetitive
effects
settlements
novel
approach
without
support
statute
discourage
settlement
patent
litigation
respectfully
dissent
point
antitrust
law
encourage
competitive
markets
promote
consumer
welfare
point
patent
law
grant
limited
monopolies
way
encouraging
innovation
thus
patent
grants
right
exclude
others
profiting
patented
invention
dawson
chemical
rohm
haas
provides
exception
antitrust
law
scope
patent
rights
conferred
patent
forms
zone
within
patent
holder
may
operate
without
facing
antitrust
liability
go
without
saying
part
said
many
times
walker
process
equipment
food
machinery
chemical
patent
exception
general
rule
line
material
precise
terms
grant
define
limits
patentee
monopoly
area
patentee
freed
competition
general
elec
patentee
steps
scope
patent
rights
comes
within
operation
sherman
act
simpson
union
oil
similar
thus
although
per
se
unlawful
fix
prices
antitrust
law
long
recognized
patent
holder
entitled
license
competitor
sell
product
condition
competitor
charge
certain
fixed
price
see
general
elec
supra
never
held
violates
antitrust
law
competitor
refrain
challenging
patent
extension
long
recognized
settlement
patent
litigation
violate
antitrust
laws
standard
oil
indiana
legitimately
conflicting
claims
threatened
interferences
settlement
agreement
rather
litigation
precluded
sherman
act
like
litigation
patent
litigation
settled
time
settlements
include
agreements
clearly
violate
antitrust
law
licenses
fix
prices
agreements
among
competitors
divide
territory
ordinarily
subject
litigants
antitrust
liability
see
hovenkamp
janis
lemley
leslie
ip
antitrust
pp
ed
hereinafter
hovenkamp
key
course
patent
holder
anything
including
settling
must
act
within
scope
patent
actions
go
beyond
monopoly
powers
conferred
patent
held
actions
subject
antitrust
scrutiny
see
singer
mfg
actions
within
scope
patent
subject
antitrust
scrutiny
two
exceptions
concededly
applicable
parties
settle
sham
litigation
cf
professional
real
estate
investors
columbia
pictures
industries
litigation
involves
patent
obtained
fraud
patent
trademark
office
walker
process
equipment
supra
thus
precedent
fairly
case
solvay
paid
competitor
respect
patent
conduct
exceed
scope
patent
one
alleges
sham
litigation
solvay
patent
obtained
fraud
pto
settlement
solvay
gave
competitors
something
value
money
exchange
competitors
gave
something
value
dropping
legal
claims
put
end
litigation
dragging
three
years
ordinarily
think
good
thing
ii
today
however
announces
new
rule
willing
accept
solvay
actions
exceed
scope
patent
ante
agree
enough
immunize
agreement
antitrust
attack
ibid
according
majority
patent
holder
settles
litigation
paying
alleged
infringer
large
unjustified
payment
exchange
alleged
infringer
honor
patent
employ
antitrust
rule
reason
determine
whether
settlement
violates
antitrust
law
ante
justifications
holding
unpersuasive
first
majority
explains
patent
may
may
valid
may
may
infringed
ante
uncertainty
whether
patent
actually
valid
says
questions
regarding
legality
settlement
measur
ed
procompetitive
antitrust
policies
rather
patent
law
policy
ante
simply
conclusion
difficulty
approach
patent
holder
acting
within
scope
patent
obvious
defense
antitrust
suit
patent
allows
engage
conduct
otherwise
violate
antitrust
laws
whole
point
patent
confer
limited
monopoly
problem
correctly
recognizes
quite
certain
patent
actually
valid
competitor
infringing
always
case
plainly
question
patent
law
majority
however
assess
patent
law
issues
according
antitrust
policies
according
majority
line
material
accommodat
ed
antitrust
principles
struck
balance
patent
antitrust
law
ante
line
material
thing
rather
explained
well
settled
possession
valid
patent
patents
give
patentee
exemption
provisions
sherman
act
beyond
limits
patent
monopoly
emphasis
added
next
sentence
stated
aggregating
patents
one
control
holder
patents
escape
prohibitions
sherman
act
ibid
second
sentence
follows
conduct
aggregation
multiple
patents
goes
beyond
limits
patent
monopoly
precisely
concluded
see
suggestion
patent
statutes
authority
combine
patent
owners
fix
prices
articles
covered
respective
patents
emphasis
added
stressed
patent
holder
violate
antitrust
laws
acts
within
scope
patent
see
within
limits
patentee
rights
patent
monopoly
process
product
authorized
patent
statutes
price
limitations
patented
devices
beyond
limits
patent
monopoly
violate
sherman
act
emphasis
added
majority
suggests
hether
particular
restraint
lies
limits
patent
monopoly
conclusion
flows
applying
traditional
antitrust
principles
ante
seems
mind
regime
courts
ignore
patent
simply
conduct
antitrust
analysis
settlement
without
regard
validity
patent
patent
holder
acting
within
scope
patent
engage
unlawful
anticompetitive
behavior
simply
exercising
monopoly
rights
granted
government
behavior
unlawful
patent
invalid
infringed
scope
patent
rights
conferred
patent
determined
reference
patent
law
conceivable
set
legal
system
assess
validity
patents
questions
infringement
bringing
antitrust
suit
neither
majority
government
suggests
congress
done
second
majority
contends
precedents
make
clear
settlement
agreements
sometimes
violate
antitrust
laws
ante
carefully
worded
proposition
cites
singer
manufacturing
new
wrinkle
standard
oil
indiana
cases
stands
uncontroversial
point
patent
holder
acts
outside
scope
patent
longer
protected
antitrust
scrutiny
patent
begin
majority
description
singer
inaccurate
singer
several
patent
holders
competing
claims
entered
settlement
agreement
patents
order
disadvantage
japanese
competition
see
finding
agreement
common
purpose
suppress
japanese
machine
competition
omitted
according
majority
singer
examine
whether
assumption
three
patents
valid
patent
law
allowed
patents
holders
ante
rather
majority
contends
singer
held
agreement
violated
laws
important
part
public
interest
granting
patent
monopolies
exists
extent
public
given
novel
useful
invention
grant
ibid
quoting
singer
white
concurring
majority
singer
certainly
ask
whether
patent
law
permitted
arrangement
concluding
see
reiterating
equally
well
settled
possession
valid
patent
patents
give
patentee
exemption
provisions
sherman
act
beyond
limits
patent
monopoly
holding
limitations
exceeded
case
emphasis
added
internal
quotation
marks
omitted
see
also
hovenkamp
citing
singer
quintessential
case
patent
holders
subject
antitrust
liability
settlement
agreement
went
beyond
scope
patents
thus
conferred
monopoly
power
beyond
patent
lawfully
authorized
even
justice
white
concurrence
majority
relies
emphasized
conduct
issue
singer
collusion
patent
holders
exclude
japanese
competition
prevent
disclosure
prior
art
authorized
patent
laws
new
wrinkle
effect
explained
rice
control
barred
beyond
patent
monopoly
arrangement
made
patent
holders
pool
patents
fix
prices
products
licensees
plainly
violate
sherman
act
emphasis
added
explained
patent
holder
may
concert
members
industry
issue
substantially
identical
licenses
members
industry
terms
industry
completely
regimented
production
competitive
unpatented
products
suppressed
class
distributors
squeezed
prices
unpatented
products
stabilized
quoting
gypsum
majority
however
ignores
discussion
instead
categorizes
case
applying
antitrust
scrutiny
patent
settlement
ante
standard
oil
indiana
parties
settled
claims
regarding
competing
patented
processes
manufacturing
unpatented
product
threatened
create
monopoly
unpatented
product
explained
exchange
licenses
purpose
curtailing
supply
unpatented
product
beyond
privileges
conferred
patents
majority
therefore
right
suggest
precedents
make
clear
settlement
agreements
sometimes
violate
antitrust
laws
ante
emphasis
added
key
word
sometimes
times
spelled
precedents
cases
made
clear
patent
settlements
matter
agreements
relating
patents
subject
antitrust
scrutiny
confer
benefits
beyond
scope
patent
makes
sense
patent
exempts
holder
antitrust
laws
insofar
holder
operates
within
scope
patent
holder
steps
outside
scope
patent
longer
use
patent
defense
majority
points
case
patent
settlement
subject
antitrust
scrutiny
merely
validity
patent
uncertain
one
remarkable
surely
worth
something
years
since
sherman
act
passed
never
let
antitrust
law
cross
rubicon
next
majority
points
general
procompetitive
thrust
act
fact
facilitat
es
challenges
patent
validity
provisions
requiring
parties
patent
dispute
report
settlement
terms
ftc
antitrust
division
department
justice
ante
act
surely
seeks
encourage
competition
drug
market
like
every
law
accomplishes
ends
specific
provisions
provisions
example
allow
generic
manufacturers
enter
market
without
undergoing
duplicative
application
process
also
grant
monopoly
first
qualifying
generic
commercially
market
competing
product
see
ii
iv
iv
yes
point
provisions
encourage
competition
trite
unnecessary
say
legislation
pursues
purposes
costs
frustrates
rather
effectuates
legislative
intent
simplistically
assume
whatever
furthers
statute
primary
objective
must
law
rodriguez
per
curiam
especially
disturbing
discerns
specific
provisions
broad
policy
general
procompetitive
thrust
words
uses
policy
unsettle
established
relationship
patent
antitrust
law
ante
indeed
whatever
may
worth
congress
repeatedly
declined
enact
legislation
addressing
issue
takes
today
see
brief
actavis
citing
bills
introduced
house
senate
since
addition
consequence
settlement
terms
must
reported
ftc
department
justice
requirement
increase
role
antitrust
law
scrutinizing
patent
settlements
rather
ensures
terms
scrutinized
consistent
existing
antitrust
law
words
ensures
ftc
antitrust
division
review
settlements
make
sure
confer
monopoly
power
beyond
scope
patent
majority
suggests
pparently
reverse
payment
settlement
agreements
arise
context
pharmaceutical
drug
regulation
ante
claim
supported
empirically
anything
majority
cites
seems
unlikely
term
reverse
payment
agreement
coined
create
impression
settlements
unique
simply
highlights
fact
party
suing
ends
paying
anomaly
evidence
nefarious
plot
simply
results
fact
patent
holder
plaintiff
defendant
invalidity
counterclaim
rare
situation
intellectual
property
litigation
whatever
one
might
call
settlements
paying
alleged
infringer
drop
invalidity
claim
feature
intellectual
property
litigation
reflect
intuitive
way
settle
disputes
see
mayer
safety
see
also
schildkraut
settlements
reverse
payment
fallacy
antitrust
brief
actavis
citing
examples
extent
scores
scores
settlements
point
settlements
outside
context
private
agreements
obvious
reasons
generally
appealed
publicly
available
majority
suggests
agreements
distinct
party
claim
damages
walks
away
money
simply
stay
away
patentee
market
ante
distinction
without
difference
alleged
infringer
may
suing
patent
holder
money
suing
right
use
market
intellectual
property
worth
money
finally
majority
complains
nothing
patent
statute
gives
right
settle
faced
allegations
invalidity
ante
right
settle
generally
accompanies
right
litigate
first
place
one
contends
drivers
automobile
accident
may
settle
competing
claims
merely
statute
grants
authority
majority
suggests
right
makes
harder
eliminat
unwarranted
patent
grants
ibid
may
result
true
patent
settlements
reason
adjudicate
questions
patent
law
antitrust
principles
cases
establish
antitrust
law
business
prying
patent
settlement
long
settlement
confers
patent
holder
monopoly
power
beyond
patent
conferred
unless
course
patent
invalid
question
patent
law
antitrust
law
sum
none
reasons
supports
conclusion
patent
holder
settling
claim
patent
invalid
immunized
fact
acting
within
scope
patent
fear
attempt
limit
holding
context
patent
settlements
long
hold
iii
majority
rule
discourage
settlement
patent
litigation
simply
put
incentive
settle
immediately
settling
parties
litigate
issue
question
patent
validity
part
defense
antitrust
suit
suit
alleged
infringer
especially
awkward
position
patent
unfortunate
patent
litigation
particularly
complex
particularly
costly
one
treatise
noted
median
patent
case
goes
trial
costs
side
million
legal
fees
alone
hovenkamp
one
study
found
cost
litigation
specific
context
generic
challenging
brand
name
pharmaceutical
patent
million
per
suit
see
herman
note
stay
dilemma
examining
brand
generic
incentives
delaying
resolution
pharmaceutical
patent
litigation
colum
rev
citing
goodman
nachman
chen
morgan
stanley
equity
research
quantifying
impact
authorized
generics
acknowledges
problems
nonetheless
offers
five
sets
considerations
tells
us
overcome
concerns
sometimes
patent
settlements
adverse
effects
anticompetitive
consequences
least
sometimes
prove
unjustified
reverse
payment
threatens
work
unjustified
anticompetitive
harm
patentee
likely
possesses
power
bring
harm
practice
normally
necessary
litigate
patent
validity
answer
antitrust
question
unexplained
large
reverse
payment
normally
suggest
patentee
serious
doubts
patent
survival
using
payment
prevent
risk
competition
constitutes
relevant
anticompetitive
harm
parties
may
still
settle
ways
allowing
generic
manufacturer
enter
patentee
market
prior
patent
expiration
without
patentee
paying
challenger
stay
prior
point
ante
emphasis
added
almost
unresponsive
basic
problem
settling
patent
claim
possibly
impose
unlawful
anticompetitive
harm
patent
holder
acting
within
scope
valid
patent
therefore
permitted
precisely
antitrust
suit
claims
unlawful
means
antitrust
suit
defendant
patent
holder
want
use
validity
patent
defense
words
want
say
valid
patent
lets
therefore
see
majority
conclude
wo
normally
necessary
litigate
patent
validity
answer
antitrust
question
ante
unless
means
suggest
defendant
patent
holder
raise
patent
defense
antitrust
suit
depriving
defense
majority
means
defeats
point
patent
confer
lawful
monopoly
holder
majority
seems
think
even
patent
valid
patent
holder
violates
antitrust
laws
merely
settlement
took
away
chance
patent
declared
invalid
see
ante
payment
prevent
risk
competition
constitutes
relevant
anticompetitive
harm
emphasis
added
flawed
several
reasons
first
patent
either
valid
invalid
parties
course
know
answer
certainty
outset
litigation
hence
litigation
true
hard
legal
question
yet
adjudicated
people
know
answer
mean
answer
declares
one
yet
majority
impose
antitrust
liability
based
parties
subjective
uncertainty
legal
conclusion
assumption
offering
large
sum
reliable
evidence
patent
holder
serious
doubts
patent
true
patent
holder
may
sure
validity
patent
particularly
risk
averse
litigation
averse
willing
pay
good
deal
money
rid
chance
finding
invalidity
actually
motivating
patent
holder
apparently
question
district
courts
resolve
basis
task
trying
discern
whether
patent
holder
motivated
uncertainty
patent
legitimate
factors
like
risk
aversion
made
difficult
fact
much
evidence
party
motivation
may
embedded
legal
advice
attorney
presumably
shielded
discovery
second
majority
position
leads
absurd
results
let
say
patent
holder
sues
competitor
infringement
faces
counterclaim
patent
invalid
patent
holder
determines
risk
losing
question
validity
low
year
litigating
grows
increasingly
risk
averse
tired
litigation
concerned
company
image
pays
competitor
large
payment
ante
exchange
competitor
honor
patent
let
say
different
competitor
inspired
first
competitor
success
sues
patent
holder
seeks
similar
payment
patent
holder
recognizing
dynamic
unsustainable
litigates
suit
conclusion
way
unanimously
decides
patent
valid
according
majority
first
settlement
violate
antitrust
laws
even
though
patent
ultimately
declared
valid
first
settlement
took
away
chance
patent
invalidated
first
go
around
approach
patent
holder
may
found
liable
antitrust
law
perfectly
valid
patent
allowed
first
place
sin
settle
rather
prove
correctness
position
litigating
bitter
end
third
logic
taking
away
chance
patent
invalidated
antitrust
problem
possibly
limited
agreements
large
ibid
government
brief
acknowledges
much
suggesting
antitrust
invited
cash
payments
may
also
required
consideration
alternative
brief
petitioner
example
patent
holder
licenses
product
licensee
fixed
monopoly
price
surely
takes
away
chance
patent
challenged
licensee
according
majority
reasoning
antitrust
problem
must
analyzed
rule
reason
see
general
elec
holding
patent
holder
may
license
invention
fixed
price
indeed
solution
patent
holders
negotiate
allow
generics
market
sooner
rather
paying
money
also
takes
away
chance
generic
litigated
patent
invalidated
thus
although
question
posed
case
fundamentally
question
patent
law
whether
solvay
patent
valid
therefore
permitted
solvay
pay
competitors
honor
scope
patent
majority
declares
questions
henceforth
scrutinized
antitrust
law
unruly
rule
reason
good
luck
district
courts
must
faced
patent
settlement
weigh
likely
anticompetitive
effects
redeeming
virtues
market
power
potentially
offsetting
legal
considerations
present
circumstances
ante
see
pacific
bell
telephone
linkline
communications
repeatedly
emphasized
importance
clear
rules
antitrust
law
iv
majority
invokes
procompetitive
antitrust
policies
ante
misses
basic
point
patent
laws
promote
consumer
interests
different
way
protection
competition
one
treatise
explains
purpose
rule
reason
determine
whether
balance
practice
reasonably
likely
anticompetitive
competitively
harmless
whether
yields
lower
higher
marketwide
output
contrast
patent
policy
encompasses
set
judgments
proper
tradeoff
competition
incentive
innovate
long
run
antitrust
rule
reason
designed
judgments
adept
making
hovenkamp
omitted
majority
recognizes
high
reverse
payment
may
signal
potential
challengers
patentee
lacks
confidence
patent
thereby
provoking
challenges
ante
brushes
two
features
make
necessarily
ibid
first
points
first
challenger
gets
exclusive
period
market
generic
version
brand
name
drug
subsequent
challengers
secure
exclusivity
period
meaning
patent
holder
buys
first
challenger
bought
motivated
competitor
two
problems
argument
first
according
food
drug
administration
manufacturers
file
first
day
considered
first
applicants
share
exclusivity
period
thus
ten
generics
file
application
market
generic
drug
first
day
considered
first
applicants
see
iv
ii
bb
see
also
fda
guidance
industry
exclusivity
multiple
andas
submitted
day
july
unusual
occurrence
see
brief
generic
pharmaceutical
association
amicus
curiae
citing
ftc
data
indicating
drugs
subject
many
sixteen
generic
applications
average
number
applications
per
drug
yearly
average
never
dropped
three
applications
per
drug
second
fundamentally
days
exclusivity
simply
provides
incentive
generic
challenges
even
subsequent
generic
entitled
additional
incentive
much
nearly
much
incentive
challenge
patent
potential
challenger
context
outside
exclusivity
period
patent
holder
gives
away
notably
large
sums
money
majority
surmises
concerned
strength
patent
putting
blood
water
sharks
always
near
majority
also
points
fact
fda
enjoined
approving
generic
application
market
drug
months
brand
name
sues
generic
patent
infringement
within
days
application
filed
ante
citing
iii
according
majority
provision
chill
subsequent
generics
challenging
patent
wait
months
receiving
fda
approval
market
drug
overlooks
important
feature
law
fda
may
approve
application
months
expiration
months
district
decides
patent
invalid
infringed
iii
even
fda
wait
months
far
clear
generic
want
market
drug
prior
obtaining
judgment
invalidity
noninfringement
may
expose
ruinous
liability
infringement
irony
majority
decision
may
well
discourage
generics
challenging
pharmaceutical
patents
first
place
patent
litigation
costly
time
consuming
uncertain
see
cybor
fas
ca
fed
opinion
rader
en
banc
discussing
study
showing
federal
circuit
wholly
partially
reversed
almost
percent
claim
construction
appeals
period
brief
generic
pharmaceutical
association
amicus
curiae
citing
study
analyzing
prior
decade
cases
showing
generics
prevailed
cases
lost
cases
generics
enter
risky
terrain
careful
analysis
potential
gains
prevail
potential
exposure
lose
taking
prospect
settlements
table
limiting
settlements
earlier
entry
date
generic
may
still
many
years
future
puts
damper
generic
expected
value
going
litigation
decreases
incentive
sue
first
place
majority
assures
us
support
everything
okay
parties
settle
simply
negotiating
earlier
entry
date
generic
drug
manufacturer
rather
settling
money
ante
matter
common
sense
confirmed
experience
parties
likely
settle
broader
set
valuable
things
trade
see
brief
mediation
negotiation
professionals
amici
curiae
majority
today
departs
settled
approach
separating
patent
antitrust
law
weakens
protections
afforded
innovators
patents
frustrates
public
policy
favor
settling
likely
undermines
policy
seeks
promote
forcing
generics
step
litigation
ring
without
prospect
cash
settlements
keep
things
subject
basic
questions
patent
law
unbounded
inquiry
antitrust
law
treble
damages
famously
burdensome
discovery
see
bell
atlantic
twombly
respectfully
dissent
